Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Cost of Revenue (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Cost of Revenue for 5 consecutive years, with $863000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue changed N/A to $863000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a N/A change, with the full-year FY2025 number at $2.7 million, changed N/A from a year prior.
  • Cost of Revenue was $863000.0 for Q4 2025 at Soleno Therapeutics, down from $1.1 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $1.1 million in Q3 2025 to a low of $863000.0 in Q4 2025.